The biodistribution of 125I-BMIPP in SD rats and the effect of metabolic intervention on myocardial uptake of 125I-BMIPP were reported. The maximal myocardial uptake of 125I-BMIPP in fasted rats was 5.70ID%/g and remained constant during 1h. The myocardial uptake was 2.18ID%/g at 120min postinjection. The ratio of myocardium to blood
myocardium to liver and myocardium to lung at 30min were 3.40
2.64 and 2.88 respectively. The liver and lung showed a low uptake and rapid clearance of 125I-BMIPP. Toxicity test revealed that the tolerable dose per kg in mice was as high as 500 times that of the recommended dose for clinical application
when the in vivo and in vitro test showed that the binding of 125I-BMIPP to HSA was stable up to 2 h. Partition coefficients (logP) at pH 7.0 and 7.4 were 1.93 and 1.68 respectively. The study of metabolic intervention showed that myocardial uptake of 125I-BMIPP in the glucose-insulin group was significantly increased (P<0.05) than those of the normal control.